The US Food and Drug Administration (FDA) has approved teriflunomide to treat relapsing forms of multiple sclerosis (MS), making it the second oral agent approved for this indication. (Fingolimod was the first oral treatment approved in September 2010 for relapsing MS. Since then, changes have been made to the label to reflect FDA concerns about [...]
Honey may be a preferable treatment of cough and sleep difficulties associated with childhood URI
The US Food and Drug Administration (FDA) has approved pregabalin (Lyrica, Pfizer Inc.) for the management of neuropathic pain associated with spinal cord injury.
By taking statins, one or more patients will develop diabetes and 20% or more will experience disabling symptoms, including muscle weakness, fatigue, and memory loss
FOOD BUSINESS OPERATOR The Food Safety and Standards Act. 2006 has come into force with effect from 05th August. 2011. It defines a Food Business Operator (FBO) as a person engaged in the business of food manufacture, processing, packaging, transportation, distribution, storage and import etc. and includes food services, catering services and sale of food [...]
Vitamin K for Osteoporosis
Walnuts, like many other nuts, are great sources of protein too and they can be key replacements for animal eating. Walnuts have long been known to influence the brain and in the natural health world, they’re known as a key brain food. Now, according to research published in the British Journal of Nutrition, eating walnuts [...]
Cholecalciferol is preferred in patients with normal or mild renal impairment (GFR > 60 mL/min) with a normal intact PTH level.
In the presence of secondary hyperparathyroidism, which usually begins in stage 3 or 4 of CKD (GFR 30-59 mL/min and 15-29 mL/min, respectively), the preferred agent for supplementation is an activated vitamin D sterol (eg, calcitriol).
Taking antihypertensive medications at bedtime rather than in the morning has been shown to be associated with an increase in bedtime blood pressure (BP) decline toward a dipping pattern and better BP control and reduction in urinary protein excretion. Nocturnal hypertension is more common among patients with chronic kidney disease (CKD) who may thus experience greater effects of time medications for hypertension.
Ursodeoxycholic acid (UDCA) is used in the treatment of cholestatic liver diseases, gallstone dissolution, and for patients with hepatitis C virus infection to ameliorate elevated alanine aminotransferase levels. The efficacy of UDCA treatment has been debated and the mechanisms of action in humans have still not defined. Suggested mechanisms include the improvement of bile acid transport and/or detoxification, cytoprotection, and anti-apoptotic effects.